Increased monocyte and T-cell activation in treated HIV+ Ugandan children: associations with gut alteration and HIV factors.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
20
2
2020
medline:
9
3
2021
entrez:
20
2
2020
Statut:
ppublish
Résumé
The pathophysiology of immune activation and its mechanisms in children living with perinatally acquired HIV (PHIV) in sub-Saharan Africa has been understudied. We enrolled 101 children living with PHIV and 96 HIV-negative controls (HIV-). All participants were between 10 and 18 years of age with no known active infections. PHIVs were on ART with HIV-1 RNA level 400 copies/ml or less. We measured plasma and cellular markers of monocyte activation, T-cell activation (expression of CD38 and HLA-DR on CD4 and CD8), oxidized lipids, markers of gut integrity and fungal translocation. Spearman correlations and linear regression models were used. Overall median (Q1; Q3) age was 13 years (11; 15) and 52% were girls. Groups were similar by age, sex and BMI. Median ART duration was 10 years (8; 11). PHIVs had higher monocyte and T-cell activation; higher sCD14 (P = 0.01) and elevated frequencies of nonclassical monocytes (P < 0.001 for both). Markers of systemic inflammation (hsCRP), fungal translocation (BDG), intestinal permeability (zonulin) and oxidized lipids (ox LDL) correlated with monocyte and T-cell activation in PHIV (≤0.05). After adjusting for age, sex, ART duration, protease inhibitor and nonnucleoside reverse transcriptase inhibitor use, a modest association between BDG and activated CD4 T cells was observed (β=0.65, P < 0.01). Oxidized LDL was inversely associated with activated T cells, inflammatory and nonclassical monocytes (P < 0.01). Ugandan children with perinatally acquired HIV with viral suppression have evidence of ongoing immune activation. Intestinal barrier dysfunction and fungal translocation may be involved in chronic immune dysfunction.
Identifiants
pubmed: 32073452
doi: 10.1097/QAD.0000000000002505
pmc: PMC7433014
mid: NIHMS1575449
pii: 00002030-202006010-00005
doi:
Substances chimiques
Anti-HIV Agents
0
Antibodies, Fungal
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1009-1018Subventions
Organisme : NICHD NIH HHS
ID : K23 HD088295
Pays : United States
Organisme : NIDDK NIH HHS
ID : R21 DK118757
Pays : United States
Organisme : NIDDK NIH HHS
ID : R21 DK127522
Pays : United States
Références
McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS (London, England) 2012; 26:1371–1385.
Stone CA, Kawai K, Kupka R, Fawzi WW. Role of selenium in HIV infection. Nutrition reviews 2010; 68:671–681.
Vyboh K, Jenabian MA, Mehraj V, Routy JP. HIV and the gut microbiota, partners in crime: breaking the vicious cycle to unearth new therapeutic targets. J Immunol Res 2015; 2015:614127.
Bowman ER, Kulkarni M, Gabriel J, Cichon MJ, Riedl K, Belury MA, et al. Altered lipidome composition is related to markers of monocyte and immune activation in antiretroviral therapy treated human immunodeficiency virus (HIV) infection and in uninfected persons. Front Immunol 2019; 10:785.
Kelesidis T, Jackson N, McComsey GA, Wang X, Elashoff D, Dube MP, et al. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS 2016; 30:2625–2633.
Godfrey C, Bremer A, Alba D, Apovian C, Koethe JR, Koliwad S, et al. Obesity and fat metabolism in human immunodeficiency virus–infected individuals: immunopathogenic mechanisms and clinical implications. J Infect Dis 2019; 220:420–431.
Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203:1474–1483.
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–1371.
Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013; 26:2–18.
Eckard AR, Rosebush JC, Lee ST, O’Riordan MA, Habib JG, Daniels JE, et al. Increased immune activation and exhaustion in HIV-infected youth. Pediatr Infect Dis J 2016; 35:e370–e377.
Sainz T, Alvarez-Fuente M, Navarro ML, Diaz L, Rojo P, Blazquez D, et al. Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study. J Acquir Immune Deficiency Syndr 2014; 65:42–49.
Cotugno N, Douagi I, Rossi P, Palma P. Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment. Clin Dev Immunol 2012; 2012:805151.
Ssewanyana I, Elrefaei M, Dorsey G, Ruel T, Jones NG, Gasasira A, et al. Profile of T cell immune responses in HIV-infected children from Uganda. J Infect Dis 2007; 196:1667–1670.
Roider JM, Muenchhoff M, Goulder PJ. Immune activation and paediatric HIV-1 disease outcome. Curr Opin HIV AIDS 2016; 11:146–155.
Milaniak I, Jaffee SR. Childhood socioeconomic status and inflammation: a systematic review and meta-analysis. Brain Behav Immun 2019; 78:161–176.
Prendergast A, Kelly P. Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hygiene 2012; 86:756–763.
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525–1533.
Calderon-Garciduenas L, Villarreal-Calderon R, Valencia-Salazar G, Henriquez-Roldan C, Gutierrez-Castrellon P, Torres-Jardon R, et al. Systemic inflammation, endothelial dysfunction, and activation in clinically healthy children exposed to air pollutants. Inhal Toxicol 2008; 20:499–506.
UNAIDS. UNAIDS report 2019. 2019.
Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588–595.
Dirajlal-Fargo S, El-Kamari V, Weiner L, Shan L, Sattar A, Kulkarni M, et al. Altered intestinal permeability and fungal translocation in Ugandan children with HIV. Clin Infect Dis 2019.
Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, Glatz JF. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin biochem 2003; 36:529–535.
El Kamari V, Moser C, Hileman CO, Currier JS, Brown TT, Johnston L, et al. Lower pretreatment gut integrity is independently associated with fat gain on antiretroviral therapy. Clin Infect Dis 2018; 68:1394–1401.
Zidar DA, Juchnowski S, Ferrari B, Clagett B, Pilch-Cooper HA, Rose S, et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. J Acquir Immune Defic Syndr 2015; 69:154–160.
Eckard AR, Rosebush JC, O’Riordan MA, Graves CC, Alexander A, Grover AK, et al. Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation. Antivir Ther 2017; 22:669–680.
Alvarez P, Mwamzuka M, Marshed F, Kravietz A, Ilmet T, Ahmed A, et al. Immune activation despite preserved CD4 T cells in perinatally HIV-infected children and adolescents. PloS One 2017; 12:e0190332.
Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, Van Dyke RB. Pediatric AIDS Clinical Trials Group219/219C TeamDeclines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010; 53:86–94.
Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Ann Rev Med 2010; 61:169–185.
Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses 2019; 11: pii: E200.
pii: e200
Dirajlal-Fargo S, Musiime V, Cook A, Mirembe G, Kenny J, Jiang Y, et al. Insulin resistance and markers of inflammation in HIV-infected Ugandan children in the CHAPAS-3 Trial. Pediatr Infect Dis J 2017; 36:761–767.
Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep 2017; 14:93–100.
Hileman CO, Kinley B, Scharen-Guivel V, Melbourne K, Szwarcberg J, Robinson J, et al. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis 2015; 212:345–354.
Organization WH. Update of recommendations on first and second-line antiretroviral regimens. Geneva, Switzerland; 2019 July 2019. Report No. WHO/CDS/HIV/19.15.
Weiner LD, Retuerto M, Hager CL, El Kamari V, Shan L, Sattar A, et al. Fungal Translocation is associated with immune activation and systemic inflammation in treated HIV. AIDS Res Hum Retrovirus 2019; 35:461–472.
Hileman CO, Turner R, Funderburg NT, Semba RD, McComsey GA. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS 2016; 30:65–73.
Rhoads JP, Major AS. How oxidized low-density lipoprotein activates inflammatory responses. Crit Rev Immunol 2018; 38:333–342.
Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, et al. Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation. Sci Transl Med 2019; 11: pii: eaav0537.
pii: eaav0537
Ajamian M, Steer D, Rosella G, Gibson PR. Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems. PloS One 2019; 14:e0210728.